Загрузка...
2452. Treatment and Outcomes of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Bloodstream Infections
BACKGROUND: Daptomycin (dap) is approved as an alternative to vancomycin (van) for therapy of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI). Cases of therapy failure associated with the emergence of daptomycin-nonsusceptible (DNS) MRSA strains have been documented. I...
Сохранить в:
| Опубликовано в: : | Open Forum Infect Dis |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6255085/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.2105 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|